PXL770



NAME OF DRUG : PXL770

ALSO KNOWN AS : PXL770

LABORATORY : POXEL

STATUS AND ADVANCEMENT

Type of drug : (AMPK) activator

Clinical trials advancement : Ongoing Phase 1

Estimated time to market : 129 months.

LABORATORY ABSTRACT ON THE DRUG

PXL770 is a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator. AMPK is a central regulator of multiple metabolic pathways leading to the control of lipid metabolism, glucose homeostasis and inflammation. Based on its central metabolic role, targeting AMPK offers the opportunity to pursue a wide range of indications to treat chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH).

KNOWN RESULTS

Here is the poster presented at the AASDL 2018

POXEL POSTER ON PXL770 AASLD 2018

 

RECENT NEWS ON PXL770

2018-02-27 : Poxel Presents Preclinical Proof-of-Concept Data for PXL770 in Non-Alcoholic Steatohepatitis (NASH) at Global NASH Congress 2018

SOME PUBLICATIONS RELATED WITH PXL770

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH PXL770


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE